Literature DB >> 9052759

Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines.

P Thor Straten1, A F Kirkin, T Seremet, J Zeuthen.   

Abstract

TAP1 and TAP2 molecules are involved in the transport of peptides prior to their association with class I molecules and are mandatory for efficient antigen presentation. To investigate whether loss of expression of TAP1 or TAP2 is a likely mechanism of immune escape in malignant melanoma, TAP1 and TAP2 mRNA was analyzed by RT-PCR in 39 melanoma cell lines expressing at least 2 of the known melanoma-associated antigens, tyrosinase, Melan-A/MART-1, gp100, MAGE-1 and MAGE-3. All 39 cell lines expressed both TAP1 and TAP2 at the mRNA level. To investigate other factors potentially involved in immune escape, the expression of LMP2, LMP7, HLA class I molecules, beta2-microglobulin (beta2m) and specific HLA-A alleles was evaluated by RT-PCR and FACS analyses. All 39 cell lines expressed LMP2, LMP7 and beta2m. A single cell line (FM37) had lost the expression of class I molecules, and this same cell line showed loss of expression of the HLA-A2 heavy chain. No cell lines showed loss of expression of the HLA-A1 heavy chain. Based on our studies of in vitro established cell lines, loss of TAP1/2 or LMP2/7 expression does not appear to be a common mechanism of immune escape in malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052759     DOI: 10.1002/(sici)1097-0215(19970304)70:5<582::aid-ijc15>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene.

Authors:  M Chatterjee-Kishore; K L Wright; J P Ting; G R Stark
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

2.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.

Authors:  T Kageshita; S Hirai; T Ono; D J Hicklin; S Ferrone
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

3.  Heterozygote of TAP1 Codon637 decreases susceptibility to HPV infection but increases susceptibility to esophageal cancer among the Kazakh populations.

Authors:  Ningjing Zou; Lan Yang; Ling Chen; Tingting Li; Tingting Jin; Hao Peng; Shumao Zhang; Dandan Wang; Ranran Li; Chunxia Liu; Jinfang Jiang; Lianghai Wang; Weihua Liang; Jianming Hu; Shugang Li; Chuanyue Wu; Xiaobin Cui; Yunzhao Chen; Feng Li
Journal:  J Exp Clin Cancer Res       Date:  2015-07-25

4.  Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.

Authors:  Alexei F Kirkin; Karine N Dzhandzhugazyan; Per Guldberg; Johnny Jon Fang; Rikke S Andersen; Christina Dahl; Jann Mortensen; Tim Lundby; Aase Wagner; Ian Law; Helle Broholm; Line Madsen; Christer Lundell-Ek; Morten F Gjerstorff; Henrik J Ditzel; Martin R Jensen; Walter Fischer
Journal:  Nat Commun       Date:  2018-03-06       Impact factor: 14.919

5.  Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.

Authors:  Manja Idorn; Signe Koggersbøl Skadborg; Lauge Kellermann; Hólmfrídur Rósa Halldórsdóttir; Gitte Holmen Olofsson; Özcan Met; Per Thor Straten
Journal:  Oncoimmunology       Date:  2018-04-18       Impact factor: 8.110

6.  Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells.

Authors:  Yuexin Pan; Jerzy Trojan; Yajun Guo; Donald D Anthony
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

7.  Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasia.

Authors:  Camilla Natter; Stephan Polterauer; Jasmin Rahhal-Schupp; Dan Cacsire Castillo-Tong; Sophie Pils; Paul Speiser; Robert Zeillinger; Georg Heinze; Christoph Grimm
Journal:  Dis Markers       Date:  2013-07-28       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.